Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery
Open Access
- 21 July 2025
- journal article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (27) , e02019
Abstract
Effective siRNA delivery in acute lymphoblastic leukemia (ALL) is limited by preferential hepatic accumulation. To address this, a lipopolymer (PEI‐C) is developed by conjugating lipid to polyethylenimine and formulated lipopolymer nanoparticles (LPNPs) via complexation with siRNA. The siRNA delivery efficiency of LPNPs is evaluated in vitro in t(4;11)‐positive ALL cells (RS4;11 and SEM) as well as “normal” peripheral blood mononuclear cells (PBMCs) from human donors and bone marrow stromal cells (BMSCs) from mice. Molecular effects are assessed by quantifying target mRNA silencing and downstream apoptosis. In vivo biodistribution and therapeutic efficacy are examined in mouse models. LPNPs demonstrated significantly higher siRNA uptake than commercial reagents in PBMCs and BMSCs, reaching siRNA uptakes of 87.2% and 93.0% in RS4;11 and SEM cells, respectively. Molecular analyses revealed effective silencing of KMT2A::AFF1 mRNA (≈80% in RS4;11), accompanied by BCL2 downregulation and increased apoptosis. In vivo, LPNPs showed efficient siRNA biodistribution to leukemia‐associated organs (spleen and bone marrow) and significantly reduced leukemia burden in a systemic RS4;11 xenograft mouse model and improved survival. These findings suggest that PEI‐C‐formulated LPNPs present a promising avenue for therapeutic siRNA delivery in ALL, effectively targeting leukemia‐associated organs, and warrant further exploration in clinical studies.Keywords
Funding Information
- Mitacs
- Edmonton Civic Employees Charitable Assistance Fund
- Canadian Institutes of Health Research
- Canadian Cancer Society (Canadian Cancer Society 2023 Challenge Grant (CHA‐24))
This publication has 65 references indexed in Scilit:
- KMT2A-rearranged acute lymphoblastic leukaemiaEJC Paediatric Oncology, 2024
- Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemiaActa Biomaterialia, 2024
- Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal modelsJournal of Controlled Release, 2024
- Linoleic‐acid‐substituted polyethylenimine to silence heat shock protein 90B1 (HSP90B1) to inhibit migration of breast cancer cellsThe Journal of Gene Medicine, 2022
- Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapyJournal of Biomedical Materials Research Part A, 2019
- siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymersJournal of Controlled Release, 2019
- MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationExperimental Hematology, 2016
- MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Cell Reports, 2015
- Poly(ethylenimine) conjugated bioreducible dendrimer for efficient gene deliveryJournal of Controlled Release, 2015
- Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulationJournal of Controlled Release, 2013